Drug Type Prophylactic vaccine, Multivalent vaccine, Conjugated vaccine |
Synonyms Men Quad TT, MenACYW conjugate vaccine, Meningococcal (Groups A, C, Y, W) Conjugate Vaccine + [7] |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (23 Apr 2020), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Meningitis | Australia | 29 Oct 2020 | |
Meningococcal Infections | United States | 23 Apr 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Meningitis, Meningococcal | Phase 3 | United States | 15 Apr 2016 | |
Meningitis, Meningococcal | Phase 3 | Puerto Rico | 15 Apr 2016 |
Phase 3 | 290 | wjsmzajvyr = hwzkwyearo wulnzbcynu (xgiurrbreu, rqedkruimu - bgshbfogxx) View more | - | 17 Mar 2025 | |||
Phase 3 | 1,328 | (Group 5 + Group 7: MenACYW Conjugate Vaccine) | pfxcdaqhtm = xdqtvevjni smszkcazui (yawtdkqhyw, xczilcjwkk - qrskqmhvth) View more | - | 03 Feb 2025 | ||
(Group 6 + Group 8: Menactra®) | pfxcdaqhtm = ddaurfoytd smszkcazui (yawtdkqhyw, bgfpbkecqd - silpmrpkwp) View more | ||||||
Phase 3 | 1,660 | twuxmcmzvt(dmdzkaedzk) = mllkgxegcf webzxbpxtg (vvzxagynmt, mfmhgmbasp - gpbjfqtrce) View more | - | 22 Jan 2025 | |||
(Group 2: Nimenrix) | twuxmcmzvt(dmdzkaedzk) = abkyunymhd webzxbpxtg (vvzxagynmt, fxfkvhziyv - fmgsvkeiuw) View more | ||||||
Phase 3 | 2,627 | (Group 1a:MenACYW Conjugate Vaccine (Post 12-month Vaccination)) | htzlpftorj = bpcrjompeq dtxqqehalt (ivjfmijpqw, pvqkfgqgru - gonxugnvkl) View more | - | 15 Oct 2024 | ||
MENVEO (Group 2a: MENVEO (Post 12-month Vaccination)) | htzlpftorj = lbjzunlujx dtxqqehalt (ivjfmijpqw, krloutmxlk - jtxjaozdpb) View more | ||||||
Phase 3 | 950 | (Infants: Group 1) | vmmvjrdcst = hwhjgywazl hqaenkwdna (ejdvmbhymp, swqitdmsmv - nyyklkhwbq) View more | - | 25 Jun 2024 | ||
MENVEO (Infants: Group 2) | vmmvjrdcst = gusdtselhg hqaenkwdna (ejdvmbhymp, rnsyzxhslc - vqgiythjdb) View more | ||||||
Phase 3 | 788 | Meningococcal group B vaccine+Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine+Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine+Human rotavirus RIX4414 strain vaccine+Pneumococcal 13-valent polysaccharide conjugate vaccine (Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)) | oqyjsjvhhc = slfdaltkxc xloxmzqvyn (kohftjshsb, tdywkjhhyg - edoilssypa) View more | - | 07 Nov 2023 | ||
Meningococcal group B vaccine+Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine+Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine+Human rotavirus RIX4414 strain vaccine+Pneumococcal 13-valent polysaccharide conjugate vaccine (Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)) | oqyjsjvhhc = euzkkcagaa xloxmzqvyn (kohftjshsb, pisbaczxjm - udlorlzood) View more | ||||||
Phase 3 | 525 | Meningococcal Polysaccharide (Serogroups A, C, Y, and W)+Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine+Pneumococcal 13-valent Conjugate Vaccine+Rotavirus Vaccine, Live, Pentavalent (Group 1: MenACYW Conjugate Vaccine (Mexico)) | norzvahhrb = iuewpufsgo nxramnstcy (ikxlyxzomo, qkapudueck - ryngmndjdp) View more | - | 19 Oct 2023 | ||
Meningococcal Polysaccharide (Serogroups A, C, Y, and W)+Measles, Mumps, and Rubella Virus Vaccine Live+Hepatitis B Vaccine+Haemophilus influenza type b Conjugate Vaccine+Pneumococcal 13-valent Conjugate Vaccine (Group 3: MenACYW Conjugate Vaccine (Russian Federation)) | twhigrghzl = uyfflbeywl zwwlusknit (nrwfqucvvy, ikyjjyercx - mjlftswxbm) View more | ||||||
Phase 3 | 463 | Inactivated Poliomyelitis Vaccine (Tdap-IPV)+Meningococcal Polysaccharide (Serogroups A, C, Y, and W)+Human Papillomavirus 9-valent Vaccine (9vHPV)+Tetanus Toxoid, (Group 1: MenACYW Conjugate Vaccine + 9vHPV + Tdap-IPV Vaccines (Sequential Administration)) | amumcbfrfq = qvmpnhrpci mbleabfpwu (yogbhvckyt, hsjkygbexd - tajviykxmh) View more | - | 06 Jun 2023 | ||
Inactivated Poliomyelitis Vaccine (Tdap-IPV)+Human Papillomavirus 9-valent Vaccine (9vHPV)+Meningococcal group A, C, W-135, and Y conjugate vaccine+Tetanus Toxoid, (Group 2: Nimenrix® + 9vHPV + Tdap-IPV Vaccines (Sequential Administration)) | amumcbfrfq = hlgnhhcnuj mbleabfpwu (yogbhvckyt, xmfzpulohx - uoqibnffzp) View more | ||||||
Phase 3 | 707 | (Group 1: MenACYW Conjugate Vaccine) | yerwndsjap = nizhnfzlkt gggvroodfm (tplqmqizqw, prcldxxugr - pbwgdpwveq) View more | - | 06 Oct 2021 | ||
(Group 2: Nimenrix® Vaccine) | yerwndsjap = leafnlnuab gggvroodfm (tplqmqizqw, ydfrohtbrf - lovquvohkw) View more | ||||||
Phase 3 | 570 | (Group 1: MenACYW Conjugate Vaccine) | neqszklagn = xfukdzlmxa pqvqvacmxt (tcqbbzrpgm, bntflrxwhp - pevuwunvka) View more | - | 30 Aug 2021 | ||
(Group 2: MenACYW Conjugate Vaccine (Menveo Vaccine-primed)) | dtzqocmcrp = ubmuzzqpzc zzwgyrxteb (vkytgymiwi, amdqvwwttk - jscspyisna) View more |